2016 American Transplant Congress
Combined CD122 and Costimulation Blockade Prolongs Allograft Survival by Controlling Expansion and Effector Function of Memory CD8 T Cells.
1Emory Transplant Center, Emory University, Atlanta, GA; 2JN Biosciences, Mountain View, CA.
CD8 memory T cells rely on signaling through CD122, the shared IL-2 and IL-15 receptor β-chain. The addition of anti-CD122 to costimulation blockade prolongs graft…2015 American Transplant Congress
Targeting Leukocyte Integrin CD11b/CD18 With a Novel mAb Salvages Renal Function Following an Otherwise Irreversible Ischemic Insult in Cynomolgus Monkeys
Allograft dysfunction resulting from ischemic reperfusion injury (IRI) leads to increased peri-transplant costs, morbidity, and inferior long-term survival. Leukocyte/endothelial adhesion is an important pathway contributing…2015 American Transplant Congress
Eculizumab in the Treatment of Early Severe Acute Antibody Mediated Rejection Following HLA-Compatible Kidney Transplantation-Case Series
Severe early acute antibody-mediated rejection (AMR) is associated with poor allograft outcomes. Eculizumab is a humanized mouse monoclonal antibody against complement factor C5 that has…2015 American Transplant Congress
The Best Regimen With Rituximab for ABO-Incompatible Living Donor Liver Transplantation
Rituximab made a great progress on outcomes of ABO-incompatible living donor liver transplantation (ABO-I LDLT). Although Japanese multicenter study group published efficacy and safety of…2015 American Transplant Congress
Infectious Complications in ABO Incompatible Kidney Transplantation Recipient According to the Rituximab Dose
BackgroundDesensitization with rituximab and intravenous immunoglobulin improves ABO incompatible (ABOi) kidney transplantation (KT) outcomes. However, infections have been noted in association with rituximab administration. In…
- « Previous Page
- 1
- …
- 3
- 4
- 5